Play Bio Menace like it's 1993. Or at least, how your time-ravaged brain remembers it.

Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week ...

Publisher Apogee Entertainment and developer Trigger Happy Interactive have announced the psychological survival horror game, Total Chaos, is now available for the PlayStation 5, Xbox Series X|S, PC ...

Publisher Apogee Entertainment and developer Trigger Happy Interactive made an appearance at the Xbox Partner Preview to announce their first-person psychological horror game, Total Chaos, doesn’t ...

The November 2025 Xbox Partner Preview has come to a close after showing off sneak peeks at games like Armatus, Raji: Kaliyuga, 007 First Light, Vampire Crawlers, and more. The 30ish-minute ...

Apogee’s ‘Rise of the Triad: Ludicrous Edition’ Finally Hits Consoles Today [Trailer] Finally, console gamers can get in on the revamped old-school Fps fun of Rise of the Triad: Ludicrous Edition that ...

Apogee Enterprises' chief executive, Ty Silberhorn, is leaving the architectural products and services company. Apogee on Friday said its independent chairman, Donald Nolan, will now serve as ...

Apogee Enterprises, Inc. (Nasdaq: APOG) announced today that Apogee Enterprises’ Independent Chair Donald A. Nolan has been appointed as the Company’s Chief Executive Officer, effective October 31, ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent through less frequent dosing and strong Phase 2 efficacy. APGE's recent $300M fundraising and analyst ...

Today at DreadXP's annual Indie Horror Showcase, Apogee Entertainment and developer Trigger Happy Interactive debuted a new gameplay trailer for the highly anticipated psychological survival horror ...

The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort. Apogee, a clinical-stage biotech that focuses on immunology and inflammation disorders, announced a ...